Payment overview · 2025
General Payments
$644.56
34 reported records · 15 companies
Healthcare provider profile · identity verified
Paul B Stringfellow, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CROWLEY, LA · NPI 1831165133
Verified facts
What the public records show
CMS Open Payments records show Paul B Stringfellow, M.D. received $644.56 in general payments during 2025 across 34 reported records.
ABBVIE INC. accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Mounjaro, Ozempic, Rexulti, Rybelsus, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BYETTA as an associated drug or biological on 60 records involving 49 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Byetta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $147.20 | 22.8% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $117.38 | 18.2% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $62.85 | 9.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.96 | 7.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.33 | 6.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.15 | 5.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.97 | 5.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $33.95 | 5.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.76 | 4.3% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $18.37 | 2.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.12 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.28 | 2.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.01 | 2.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.65 | 2.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.58 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $644.56 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $85.16 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $81.71 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $81.71 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $65.49 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $62.85 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $38.33 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $38.33 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $35.13 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.97 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $32.22 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $27.76 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.71 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 49 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 113 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 17 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BYETTA open payments reported associated product |
CMS Open Payments — General Payments 60 supporting records · 49 recipient NPIs · example record 1206154618 |
Byetta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
49 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
17 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
113 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
202 | 28 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
166 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 761 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 623 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 404 | 77 |
| Furosemide | Furosemide | 372 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 68 |
| Omeprazole | Omeprazole | 338 | 76 |
| Metformin Hcl | Metformin Hcl | 307 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 300 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 285 | 47 |
| Prednisone | Prednisone | 249 | 133 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 41 |
| Ezetimibe | Ezetimibe | 209 | 35 |
| Trulicity | Dulaglutide | 202 | 28 |
| Azithromycin | Azithromycin | 199 | 136 |
| Irbesartan | Irbesartan | 184 | 39 |
| Doxazosin Mesylate | Doxazosin Mesylate | 175 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 31 |
| Gabapentin | Gabapentin | 169 | 40 |
| Eliquis | Apixaban | 166 | 22 |
| Lisinopril | Lisinopril | 164 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 157 | 46 |
| Potassium Chloride | Potassium Chloride | 156 | 29 |
| Losartan Potassium | Losartan Potassium | 152 | 31 |
| Trazodone Hcl | Trazodone Hcl | 146 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 23 |
| Carvedilol | Carvedilol | 129 | 18 |
| Finasteride | Finasteride | 129 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 31 |
| Famotidine | Famotidine | 128 | 27 |
| Valsartan | Valsartan | 127 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 121 | 21 |
| Warfarin Sodium | Warfarin Sodium | 121 | 12 |
| Sertraline Hcl | Sertraline Hcl | 118 | 23 |
| Ozempic | Semaglutide | 115 | 18 |
| Mounjaro | Tirzepatide | 113 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 112 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 25 |
| Memantine Hcl | Memantine Hcl | 106 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 94 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 17 |
| Donepezil Hcl | Donepezil Hcl | 87 | suppressed |
| Pregabalin | Pregabalin | 87 | 24 |
| Allopurinol | Allopurinol | 86 | 22 |
| Diazepam | Diazepam | 85 | 24 |
| Tramadol Hcl | Tramadol Hcl | 85 | 19 |
| Glimepiride | Glimepiride | 78 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 11 |
| Mupirocin | Mupirocin | 72 | 40 |
| Clonazepam | Clonazepam | 71 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 24 |
| Fluconazole | Fluconazole | 65 | 44 |
| Linzess | Linaclotide | 64 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 43 |
| Meloxicam | Meloxicam | 56 | 19 |
| Alprazolam | Alprazolam | 53 | 15 |
| Clonidine Hcl | Clonidine Hcl | 52 | suppressed |
| Anastrozole | Anastrozole | 51 | suppressed |
| Spironolactone | Spironolactone | 50 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 49 | 49 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Digoxin | Digoxin | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 15 |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 32 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 31 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 15 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Naproxen | Naproxen | 29 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 22 |
| Methylphenidate Hcl | Methylphenidate Hcl | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 19 |
| Sulfasalazine Dr | Sulfasalazine | 25 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 16 |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Entacapone | Entacapone | 22 | suppressed |
| Jantoven | Warfarin Sodium | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Ertapenem | Ertapenem Sodium | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 20 | 15 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Ursodiol | Ursodiol | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Byetta | Exenatide | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Clarithromycin | Clarithromycin | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $644.56 · 34 records | ABBVIE INC. | ABRYSVO, AREXVY, CAPLYTA, COMIRNATY, Cologuard Collection Kit, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, IBSRELA, JARDIANCE, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, WATCHMAN Access System, Wegovy, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error